Clinical trials · Pittsburgh, PA
Neoplasms clinical trials in Pittsburgh
We’re tracking 70 recruiting neoplasms studies with a site in or near Pittsburgh — including Early Phase 1, Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Pittsburgh
- NCT03816345RecruitingPhase 1
Nivolumab for advanced cancer with autoimmune disease
This trial tests whether the immunotherapy drug nivolumab can safely treat advanced cancer in people who also have an autoimmune disease like rheumatoid arthritis, lupus, or multiple sclerosis. It aims to find out if the drug may help control cancer while managing their autoimmune condition.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06388967Recruiting
Pancreatic cancer detection study
This study is looking at blood or tissue samples from people with pancreatic cancer and from those without it. The goal is to find ways to detect the cancer earlier.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT05253651RecruitingPhase 3
Tucatinib plus trastuzumab with chemo for HER2+ metastatic colon cancer
This trial tests whether adding tucatinib and trastuzumab to standard chemotherapy works better than standard treatment alone for people with HER2-positive metastatic colon or rectal cancer. It aims to improve how long people live and how well tumors respond as first treatment for advanced disease.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT04585958RecruitingPhase 1
Combination treatment for HER2-positive cancers and resistant ovarian cancer
This trial tests a new combination of two drugs, DS-8201a and olaparib, for people with cancers that have a protein called HER2, and for those with ovarian cancer that has stopped responding to platinum chemotherapy. The goal is to see if this combination can shrink or control the cancer.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06513962RecruitingPhase 3
Triptorelin to protect ovaries in young women with cancer
This study tests whether a medicine called triptorelin can protect the ovaries in young women and teens receiving strong chemotherapy for cancer. If you are newly diagnosed with a cancer (other than breast cancer) and are about to get certain chemotherapy drugs, this trial may help preserve your fertility.
Pittsburgh, PennsylvaniaAges Up to 39 years - NCT05372640RecruitingPhase 1
Drug combo trial for rare cancers with shared NUT features
This Phase 1 trial tests the safety and early signs of effectiveness of combining two anti-cancer drugs (ZEN003694 and abemaciclib) in teens and adults with metastatic or unresectable NUT carcinoma, breast cancer, and other solid tumors. It may help by finding a safer dose and whether the drug combination can shrink or control tumors that do not respond to standard treatments.
Pittsburgh, PennsylvaniaAges 12 years+ - NCT04369560RecruitingEarly Phase 1
Virtual MRI to map bladder cancer for staging before surgery
This early-stage study uses special MRI imaging to create a “virtual view” of the bladder wall so doctors can better stage bladder cancer before treatment. If you qualify, you may get MRI imaging using contrast medicines as part of planning your surgery.
Pittsburgh, PennsylvaniaAges 18–90 - NCT05855200RecruitingPhase 3
Dostarlimab around surgery for certain untreated colon cancers
This trial studies dostarlimab given around the time of colon cancer surgery for people with untreated, resectable (operable) stage T4N0 or stage III colon cancer that has specific tumor markers. It may help shrink or eliminate the cancer before or after surgery by boosting the immune response.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT05999994RecruitingPhase 2
Testing new drugs for children and young adults with cancer
This trial tests several experimental drugs for children and young adults with cancer. It aims to find safe and effective treatments by matching participants to one of several drug studies based on their cancer type and health.
Pittsburgh, PennsylvaniaAges 1–39 - NCT05691491RecruitingPhase 1/Phase 2
Temozolomide plus M1774 for advanced metastatic cancers
This Phase 1/2 trial tests a combination of temozolomide and M1774 to see how safe it is and whether it can help shrink advanced cancers that have spread. It focuses on certain tumor types and specific biomarker results, and it may be an option if standard treatments have been tried or aren’t possible.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT05554406RecruitingPhase 2
New drug therapy for high-risk AML
This trial is testing new drug combinations for people with newly diagnosed, high-risk AML who have not yet started treatment. It aims to find more effective therapies for this aggressive form of leukemia.
Pittsburgh, PennsylvaniaAges 18–59 - NCT04585750RecruitingPhase 1/Phase 2
Studying a new drug for cancers with a specific TP53 change
This trial tests a new drug (rezatapopt) for people with advanced cancers that have a specific change in the TP53 gene, called Y220C. The drug is designed to target this change and may slow or stop cancer growth. Some participants may also receive an immunotherapy drug called pembrolizumab (Keytruda).
Pittsburgh, PennsylvaniaAges 12 years+ - NCT07060807RecruitingPhase 3
Patritumab deruxtecan for advanced breast cancer
This study tests an investigational drug called patritumab deruxtecan for people with a certain type of advanced breast cancer that is hormone receptor-positive and HER2-negative. The drug targets a protein called HER3, which is common on these cancer cells, and may slow or shrink the cancer when previous treatments have stopped working.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT05564390RecruitingPhase 2
MyeloMATCH screening to match you to AML or MDS treatment
This study screens people with newly suspected acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) to see which treatment approach fits best—either a specific study treatment or standard care. It may help by directing you to the right option and by sharing your blood/bone marrow samples for research.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT04665739RecruitingPhase 2
Lutetium Lu-177 for lung carcinoid tumors with somatostatin receptors
This trial tests lutetium Lu 177 dotatate, a targeted radiation treatment, for advanced lung neuroendocrine (carcinoid) tumors that have a specific marker called somatostatin receptors. It may help shrink tumors by delivering radiation directly to cancer cells that “light up” on a special scan.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT07412002Recruiting
End-of-life care quality for children with cancer
This trial asks bereaved parents about the quality of care their child received in the last month of life. It aims to improve how hospitals support families when a child with cancer is dying.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT04239573Recruiting
Compare pancreatic cyst checkup programs and test markers
This study compares different ways to monitor pancreatic cysts and also measures blood or other test markers to see which approach is more helpful. It may help patients by finding the safest, most effective way to track certain cysts that could otherwise be hard to manage.
Bryn Mawr, PennsylvaniaAges 50–75 - NCT07309445Recruiting
Real-world use of TAR-200 for non-muscle invasive bladder cancer
This study looks at how patients with non-muscle invasive bladder cancer are using TAR-200 in everyday medical care. It aims to understand treatment patterns and outcomes outside of a clinical trial.
Bryn Mawr, PennsylvaniaAges 18 years+ - NCT03418961RecruitingPhase 3
Study of heart-risk management for metastatic HER2 breast cancer
This trial follows people with metastatic HER2-positive breast cancer who are at higher risk for heart damage while on HER2-targeted therapy. Some participants are randomly assigned to different monitoring/heart-protection approaches to see what best helps keep the heart safe.
Bryn Mawr, PennsylvaniaAges 18 years+ - NCT05334069Recruiting
Blood test study for early cancer detection in patients
This study collects blood from people with cancer and people without cancer (or with possible cancer) to test whether new blood tests can detect cancer earlier. Your blood samples help researchers evaluate how well these tests work.
Meadowbrook, PennsylvaniaAges 40–75 - NCT04871542Recruiting
Predicting risk of immune therapy side effects
This study tries to predict who is more likely to get serious side effects from immune checkpoint medicines used for solid tumors. You may help researchers by answering questionnaires before treatment and during follow-up, and by possibly storing sample specimens.
Meadowbrook, PennsylvaniaAges 18 years+ - NCT04242095Recruiting
Immunotherapy side effects research study
This study collects blood, stool, and tissue samples from people who have had side effects from immunotherapy (a type of cancer treatment that helps your immune system fight cancer). It aims to learn more about these side effects, so doctors can better manage them in the future.
Meadowbrook, PennsylvaniaAges Any age
Hear when a new Neoplasms trial opens near Pittsburgh, PA
We’ll email you when one opens near Pittsburgh, PA — at most once a week, no account needed, unsubscribe anytime.
Neoplasms trials in other cities
Where these studies are running near Pittsburgh
Institutions with a site for the recruiting neoplasms studies listed above.
- UPMC Hillman Cancer Center · 8 studies
- Redeemer Health - Holy Redeemer Hospital · 3 studies
- UPMC Children's Hospital of Pittsburgh · 3 studies
- Bryn Mawr Hospital · 2 studies
- AHN Cancer Institute at Allegheny General Hospital
- GSK Investigational Site
- MidLantic Urology - Haverford Road - Bryn Mawr
- St. Clair Cancer Center Medical Oncology
What taking part in a neoplasms study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting neoplasms studies in Pennsylvania.
Common questions
- Are there neoplasms clinical trials near Pittsburgh?
- Yes. We're currently tracking 70 recruiting neoplasms studies with a site near Pittsburgh, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a neoplasms study near Pittsburgh?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Pittsburgh to take part?
- Not necessarily. These studies have a site near Pittsburgh, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a neoplasms trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New neoplasms studies open near Pittsburgh regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.